Overview

Gender

male

Investor Type

Investment Partner

Peter Farina works with great entrepreneurs and scientists to bring innovative medicines to patients. Since 2008, he has been identifying and evaluating investment opportunities in the healthcare sciences for the Canaan team. Passionate about R&D in the fields of chemistry and biology, Peter's accomplishments in drug research include the successful development and registration of Viramune® (nevirapine) and Aptivus® for HIV, Atrovent® HFA for COPD/emphysema and Jardiance® (empagliflozin) for diabetes.

Prior to joining the team at Canaan, Peter served as Senior Vice President of Development at Boehringer Ingelheim Pharmaceuticals, where he was responsible for the North American development of drugs in the therapeutic areas of immunology/inflammation, virology and cardio/metabolic diseases. Peter also served as vice president of research, director of inflammatory diseases and director of biochemistry during his 28 year career with the company. Previously, Peter worked on the development of immunodiagnostics for the Corporate Research Laboratories and Medical Products Division of Union Carbide Corporation.